Effect of Memantine on QT/QTc Interval in a Healthy Korean Population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jin-Woo | - |
dc.contributor.author | Kim, Kyoung-Ah | - |
dc.contributor.author | Park, Ji-Young | - |
dc.date.accessioned | 2021-12-01T13:41:49Z | - |
dc.date.available | 2021-12-01T13:41:49Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 2160-763X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128599 | - |
dc.description.abstract | Studies on the effects of memantine on QT prolongation have yielded conflicting results. For a long time, memantine was reported to be a safe drug without QT prolongation; however, several case studies have reported memantine-induced QT prolongation in Alzheimer's patients. This study evaluated the relationship between memantine blood levels, and QT interval changes. Over a 2-week period, we orally administered 20 mg of memantine daily to achieve a steady state in 57 healthy Korean subjects. We measured and analyzed the QT interval and blood memantine concentrations simultaneously before and after treatment, as well as 2 weeks after the last dosing. Correlation analysis was done between blood memantine level and QT interval. No serious adverse events occurred during the study period. Repeated dosing of memantine did not show clinically significant QT interval changes after treatment. Regression analysis was performed based on the results; there was no statistical association between memantine blood level and QT prolongation. In conclusion, the results of the present study demonstrated no clinically significant changes in the QT interval with therapeutic blood levels of memantine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Effect of Memantine on QT/QTc Interval in a Healthy Korean Population | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Ji-Young | - |
dc.identifier.doi | 10.1002/cpdd.931 | - |
dc.identifier.scopusid | 2-s2.0-85102917076 | - |
dc.identifier.wosid | 000632051500001 | - |
dc.identifier.bibliographicCitation | CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, v.10, no.10, pp.1209 - 1215 | - |
dc.relation.isPartOf | CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | - |
dc.citation.title | CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | - |
dc.citation.volume | 10 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1209 | - |
dc.citation.endPage | 1215 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INDUCED QT PROLONGATION | - |
dc.subject.keywordPlus | LONG-QT | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.subject.keywordPlus | ECG MEASUREMENT | - |
dc.subject.keywordPlus | CHANNELS | - |
dc.subject.keywordPlus | VARIABILITY | - |
dc.subject.keywordPlus | STATEMENT | - |
dc.subject.keywordPlus | GENDER | - |
dc.subject.keywordPlus | AGE | - |
dc.subject.keywordAuthor | memantine | - |
dc.subject.keywordAuthor | QT | - |
dc.subject.keywordAuthor | QTc | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.